CORRECTION Open Access

Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas



Congxiao Wang¹, Shifeng Liu¹, Lijing Peng², Kaixian Zhang³, Wei Li¹, Hao Zhang¹, Ying Luan⁴, Peishun Li³ and Xiaokun Hu^{1*}

Correction to: BMC Cancer 20, 591 (2020) https://doi.org/10.1186/s12885-020-07086-8

Following publication of the original article [1], the authors identified an error in Fig. 2. The corrected Fig. 2 is given below.

Author details

¹Department of the Interventional Medical Center, the Affiliated Hospital of Qingdao University, #1677 Wutaishan Road, Qingdao 266000, Shandong, China. ²Department of Clinical Laboratory, the Affiliated Hospital of Qingdao University, Qingdao, China. ³Department of Oncology, Tengzhou Central People's Hospital, Zaozhuang 277500, Shandon, China. ⁴Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Jiangsu Key Laboratory of Molecular and Functional Imaging, Nanjing 210009, China.

Published online: 07 August 2020

Reference

 Wang C, Liu S, Peng L, et al. Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas. BMC Cancer. 2020;20:591. https://doi.org/10.1186/s12885-020-07086-8.

The original article can be found online at https://doi.org/10.1186/s12885-020-07086-8.

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: huxiaokun770@163.com

¹Department of the Interventional Medical Center, the Affiliated Hospital of Qingdao University, #1677 Wutaishan Road, Qingdao 266000, Shandong,

Wang et al. BMC Cancer (2020) 20:736 Page 2 of 2




Fig. 2 Kaplan-Meier analysis of OS and PFS **a** The median OS was 22 months in the SI group compared with 21 months in the SRCI group (p = 0.751). **b** The median PFS was 8 months in the SI group compared with 7 months in the SRCI group (p = 0.203)